• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Smith+Nephew acquires novel cementless partial knee system

    1/19/22 2:00:00 AM ET
    $SNN
    Industrial Specialties
    Health Care
    Get the next $SNN alert in real time by email

    LONDON, Jan. 19, 2022 /PRNewswire/ -- Smith+Nephew ((LSE: SN, NYSE:SNN), the global medical technology business, announces the acquisition of Engage Surgical, owner of the only cementless unicompartmental (partial) knee system commercially available in the US.

    Smith & Nephew logo. (PRNewsFoto/Smith & Nephew)

    This acquisition strongly supports Smith+Nephew's strategy for growth by transforming its business through innovation and acquisition, while also providing differentiation for its customers. The Engage Surgical Partial Knee System is a novel, modern cementless knee implant to serve a resurgent segment driven by the potential for better long-term fixation through biologic integration, shorter operating times, and the shift to Ambulatory Surgery Centers (ASCs).

    Randy Kilburn, Executive Vice President & General Manager, Reconstruction, Robotics and Digital, said:

    "Smith+Nephew is now the only medical device company offering both cemented and cementless partial knee implants in the US, as well as robotics-assistance through the CORI™ Surgical System that is well-suited for the precise alignment needed. Through our Sports Medicine franchise we have an established, strong position in ASCs where the vast majority of partial knees in the US are performed. Our VISIONAIRE™ business, the high performance and small footprint of CORI, plus our partial knee portfolio, is a unique compelling offering for customers."

    The acquisition will drive Smith+Nephew's Robotics and Real Intelligence strategy. Partial knee procedures are well-matched for robotics due to the need for precise alignment and Smith+Nephew's CORI Surgical System already supports the cemented JOURNEY II™ unicompartmental knee. The Engage Surgical Partial Knee System is optimised for robotics and will have an application with CORI in the future. Engage Surgical's Partial Knee System also complements Smith+Nephew's focus on serving the growing outpatient market, with an increasing proportion of knee procedures performed in ASCs.

    Dan Justin, Chief Executive Officer, Engage Surgical, said:

    "The Engage Surgical Team is excited about joining Smith+Nephew to help expand the impact of the Engage Surgical Partial Knee System and integrating it with the CORI Surgical System. Smith+Nephew is well-suited and well-prepared to continue our mission of providing better outcomes for knee arthroplasty patients."

    With Engage Surgical's Partial Knee System, Smith+Nephew expects to be able to drive market expansion in the US, and in time in other markets as regulatory approvals are secured. Engage Surgical's Partial Knee System currently has regulatory clearance in the US where it is in limited market release.

    The partial knee market is currently worth approximately $300 million in the US (SmartTRAK) and is expected to grow faster than the total knee market and by around 4% per annum through 2029 (Millennium Research Group, Inc). Smith+Nephew expects cementless partial knees will grow ahead of overall partial knees, in line with recent patterns seen in the cementless segment.

    The cost of the acquisition is up to $135 million contingent on sales performance. The acquisition was financed from existing cash and debt facilities. Engage Surgical is located in Orlando, Florida.

    About Smith+Nephew

    Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living. We call this purpose 'Life Unlimited'. Our 18,000 employees deliver this mission every day, making a difference to patients' lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

    Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $4.6 billion in 2020. Smith+Nephew is a constituent of the FTSE100 ((LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

    For more information about Smith+Nephew, please visit www.smith-nephew.com and follow us on Twitter, LinkedIn, Instagram or Facebook.

    Forward-looking Statements

    This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations

    ™ Trademark of Smith+Nephew. Certain marks registered US Patent and Trademark Office.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/smithnephew-acquires-novel-cementless-partial-knee-system-301463369.html

    SOURCE Smith & Nephew plc

    Get the next $SNN alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SNN

    DatePrice TargetRatingAnalyst
    4/25/2025Buy → Hold
    HSBC Securities
    3/12/2025Buy → Neutral
    UBS
    11/6/2024Buy → Hold
    Berenberg
    11/1/2024Buy → Hold
    Deutsche Bank
    7/24/2024Buy
    Deutsche Bank
    6/5/2024Neutral → Buy
    UBS
    11/28/2023Underweight → Equal Weight
    Barclays
    11/3/2023Neutral → Overweight
    JP Morgan
    More analyst ratings

    $SNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Smith & Nephew downgraded by HSBC Securities

      HSBC Securities downgraded Smith & Nephew from Buy to Hold

      4/25/25 8:30:48 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by UBS

      UBS downgraded Smith & Nephew from Buy to Neutral

      3/12/25 7:34:02 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith & Nephew downgraded by Berenberg

      Berenberg downgraded Smith & Nephew from Buy to Hold

      11/6/24 6:23:06 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Global Sports Medicine leader Smith+Nephew to sponsor select players competing at Wimbledon, highlighting advanced solutions for joint repair

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces it will once again support select players during high profile matches at The Championships, Wimbledon in 2025. The world's oldest and most prestigious tennis tournament serves as a perfect backdrop to showcase Smith+Nephew's purpose of ‘Life Unlimited' - making a difference in patients' lives through the excellence of a diverse Sports Medicine product portfolio and the application of new technologies. Tennis is a high-impact sport that places great stress on various areas of the body – especially joints – often resulting in injury. Some of the latest technologies and solutions from Smith+Nephew for joint re

      6/29/25 7:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Smith+Nephew's new TRIGEN™ MAX Tibia Nailing System brings 'next-level nailing' to trauma surgeons repairing tibial fractures

      The future of fracture fixation with novel side-specific nails featuring variable angle locking technology Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of its new TRIGEN MAX Tibia Nailing System for stable and unstable fractures of the tibia, including the shaft. It is the only system to now offer trauma surgeons the choice of side-specific (right and left) nails for anatomic screw trajectories, which help to optimize fragment fixation and minimize soft tissue irritation with headless and low-profile screw options.1, 2 The TRIGEN MAX Tibia Nailing System aims to streamline operative procedures and provide efficiency through surgeon-ce

      6/24/25 10:00:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care

    $SNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: Plc Nephew & Smith claimed ownership of 5,428,680 units of Class A Common Stock and claimed ownership of 16,534,814 units of Class B Common Stock

      3 - SMITH & NEPHEW PLC (0000845982) (Reporting)

      2/12/21 6:00:30 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    SEC Filings

    See more
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      7/1/25 11:55:37 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/13/25 11:12:35 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form 6-K filed by Smith & Nephew SNATS Inc.

      6-K - SMITH & NEPHEW PLC (0000845982) (Filer)

      6/6/25 1:20:14 PM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Leadership Updates

    Live Leadership Updates

    See more
    • Ajay Dhankhar joins Smith+Nephew as Chief Corporate Development & Strategy Officer

      Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology company, announces the appointment of Ajay Dhankhar, PhD, as Chief Corporate Development & Strategy Officer, effective today. Ajay will report to Chief Executive Officer Deepak Nath and join the Smith+Nephew Executive Committee.  As both a senior management consultant and investment banker, Ajay has advised CEOs and Boards at some of the world's leading healthcare companies, helping deliver substantial shareholder value.  Ajay's experience includes 25 years with McKinsey & Company where he was a Senior Partner and held multiple leadership roles including Global Head of Strategy across all industries, Global Head of Strategy

      6/23/25 8:00:00 AM ET
      $LAZ
      $SNN
      Investment Managers
      Finance
      Industrial Specialties
      Health Care
    • Cadence Welcomes Bob White to Board of Directors

      STAUNTON, Va., Sept. 12, 2024 /PRNewswire/ -- Cadence, Inc., a leading provider of vertically integrated contract manufacturing solutions to the MedTech and Pharma markets, is pleased to announce the appointment of Bob White to its Board of Directors.  Mr. White brings over 25 years of business leadership experience and a proven track record in operational excellence, technological innovation, and strategic growth to Cadence. Mr. White has demonstrated exceptional skills in managing global locations, having held senior positions at Medtronic, GE Healthcare, and IBM.  He recent

      9/12/24 10:57:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Financials

    Live finance-specific insights

    See more
    • Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research

      New York, United States, March 03, 2025 (GLOBE NEWSWIRE) -- The global demand for wound care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Download Free Sample Report PDF @ https://straitsresearc

      3/3/25 8:20:00 AM ET
      $SNN
      Industrial Specialties
      Health Care
    • Wound Care Market Will Reach USD 31.81 Billion by 2030 on the Back of Growth in the North American Market

      New York, United States, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The global demand for Wound Care products is increasing as the number of patients with chronic and acute wounds rises. Market leaders continually focus on introducing innovative wound care products to meet unmet demand. As a result, more people are using conventional, bioactive, and other wound care products. In addition, governments in developing nations and other for-profit and non-profit organizations are increasingly focusing on various awareness campaigns to educate the public about innovative product offerings and therapeutic options for chronic and advanced wounds. Get a Free Sample Copy of This Report https://stra

      8/29/22 3:20:00 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • Healiva® Acquires Two Wound-healing Cell Therapy Assets From Smith+Nephew

      Adds two close-to-market innovative technologies to Healiva's® growing portfolio of end-to-end care for chronic wounds Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of two innovative cell therapy assets from Smith+Nephew ((LSE:SN, NYSE:SNN), the global medical technology business. The acquisition enables Healiva® to establish one of the world's broadest portfolios of affordable, personalized, end-to-end wound care consisting of enzyme technology, autologous & allogenic cell therapies, and medical devices. Financial details have not been disclosed. The first asset, EpiDex®, is an

      6/1/22 2:30:00 AM ET
      $SNN
      Industrial Specialties
      Health Care

    $SNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Smith & Nephew SNATS Inc.

      SC 13D - SMITH & NEPHEW PLC (0000845982) (Subject)

      7/9/24 12:00:10 PM ET
      $SNN
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - SMITH & NEPHEW PLC (0000845982) (Subject)

      2/3/21 1:13:21 PM ET
      $SNN
      Industrial Specialties
      Health Care